Skip to main content

Boston Scientific Corporation (BSX)

NYSE: BSX · IEX Real-Time Price · USD
41.40
0.70 (1.72%)
At close: Dec 7, 2021 4:00 PM
41.50
0.10 (0.24%)
After-hours:Dec 7, 2021 7:17 PM EST
Market Cap58.99B
Revenue (ttm)11.47B
Net Income (ttm)1.10B
Shares Out1.42B
EPS (ttm)0.77
PE Ratio53.84
Forward PE21.32
Dividendn/a
Ex-Dividend Daten/a
Volume7,355,045
Open41.24
Previous Close40.70
Day's Range41.05 - 42.06
52-Week Range33.42 - 46.29
Beta0.87
AnalystsStrong Buy
Price Target51.20 (+23.7%)
Earnings DateOct 27, 2021

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r...

IndustryHealth Care Equipment & Supplies
IPO DateMay 18, 1992
CEOMichael Mahoney
Employees38,000
Stock ExchangeNYSE
Ticker SymbolBSX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is 51.20, which is an increase of 23.67% from the latest price.

Price Target
$51.20
(23.67% upside)
Analyst Consensus: Strong Buy

News

Here's Why You Should Retain Boston Scientific (BSX) for Now

Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.

5 days ago - Zacks Investment Research

Boston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System

MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™...

5 days ago - PRNewsWire

Boston Scientific Announces Upcoming Conference Schedule

MARLBOROUGH, Mass., Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

4 weeks ago - PRNewsWire

QIPT vs. BSX: Which Stock Should Value Investors Buy Now?

QIPT vs. BSX: Which Stock Is the Better Value Option?

Other symbols:QIPT
1 month ago - Zacks Investment Research

4 Medical Products Stocks Poised to Beat This Earnings Season

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

Other symbols:ABTCGCDGXHSICIDXXPODD
1 month ago - Zacks Investment Research

Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up

Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.

1 month ago - Zacks Investment Research

Boston Scientific Q3 Earnings Comes Inline With Wall Street Expectations

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion. Sales increased 10.3% Y/Y on a reported basis...

1 month ago - Benzinga

Boston Scientific (BSX) Q3 Earnings Beat Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Boston Scientific Q3 Earnings

Boston Scientific (NYSE:BSX) reported its Q3 earnings results on Wednesday, October 27, 2021 at 06:30 AM. Here's what investors need to know about the announcement.

1 month ago - Benzinga

Boston Scientific Announces Results For Third Quarter 2021

MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported bas...

1 month ago - PRNewsWire

Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More

With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.

Other symbols:ALGNEWTMO
1 month ago - Zacks Investment Research

Boston Scientific (BSX) Product Launches to Drive Q3 Earnings

Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.

1 month ago - Zacks Investment Research

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now

Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.

1 month ago - Zacks Investment Research

Boston Scientific (BSX) Inks New Deal to Buy Baylis Medical

The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.

1 month ago - Zacks Investment Research

Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable

Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.

1 month ago - Zacks Investment Research

Boston Scientific (BSX) Reports Data Backing Eluvia Stent

The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.

1 month ago - Zacks Investment Research

Boston Scientific's Eluvia Drug-Eluting Vascular Stent Tops Bare Metal Stents

Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting.  Data presented included on...

2 months ago - Benzinga

Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) ...

2 months ago - PRNewsWire

Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal

Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion. The acquisition will expand Boston Scientific's electrophysiology and ...

2 months ago - Benzinga

Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism

Boston Scientific Corporation (NYSE: BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting.  Related:   Boston Scientific Acquires Provider O...

2 months ago - Benzinga

Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.

MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an u...

2 months ago - PRNewsWire

Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21

LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking ...

2 months ago - PRNewsWire

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon

LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical t...

2 months ago - PRNewsWire

Boston Scientific Announces Conference Call Discussing Third Quarter 2021 Results

MARLBOROUGH, Mass., Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter end...

2 months ago - PRNewsWire